The University of Nevada, Reno School of Medicine

Where Oral Therapies Fit in an Injectable Landscape for Psoriasis Management

MD, MS

Review emerging oral therapies in the context of the current treatment landscape for psoriasis (PsO) 

Discuss considerations for PsO treatment selection, including patient preferences and treatment targets

Evaluate the safety and efficacy of oral IL-23 inhibitors to improve outcomes for patients with psoriasis 

large_iStock-1225328599 (1).jpg

medium_iStock-1225328599 (1).jpg

small_iStock-1225328599 (1).jpg

thumbnail_iStock-1225328599 (1).jpg

iStock-1225328599 (1).jpg

Psoriasis is a chronic, immune-mediated inflammatory disease characterized by dysregulated IL-23/IL-17 axis signaling and keratinocyte hyperproliferation, resulting in well-demarcated erythematous plaques with silvery scale. Beyond cutaneous involvement, psoriasis has been linked to systemic inflammation contributing to increased risk of cardiometabolic and other inflammatory comorbidities.

This hub gathers the evidence, expert perspective, and practical insight shaping how psoriasis is understood and treated today, connecting advances in targeted therapy with the everyday decisions required to manage chronic inflammation and systemic risk.

FC25: Where Oral Therapies Fit in an Injectable Landscape for Psoriasis Management

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures